<DOC>
	<DOC>NCT02157584</DOC>
	<brief_summary>This study is designed to evaluate the effect of food on the pharmacokinetics (PK) of telotristat ethyl and its metabolite LP-778902 relative to administration of single dose telotristat etiprate in the fasted state in healthy adult male and female subjects.</brief_summary>
	<brief_title>An Open-Label Food Effect Study of Telotristat Etiprate</brief_title>
	<detailed_description />
	<criteria>Healthy adult subjects aged ≥18 to ≤55 years of age at screening Body mass index ≥18.0 to ≤32.0 kg/m^2 Acceptable vital signs at Screening: Systolic blood pressure = 90140 mm Hg, Diastolic blood pressure = 5090 mm Hg, Heart rate = 40100 beats per minute Able and willing to ingest an entire high fat/high caloric breakfast meal within 30 minutes Willingness to adhere to the restrictions outlined in the protocol Able to comprehend and sign the Informed Consent Form Presence of any clinically significant physical, laboratory, or ECG finding that may interfere with the study in the opinion of the Investigator Use of any medications, herbal tea, energy drink, herbal products, or supplements within 14 days of study start Receipt of any investigational agent or study drug within 30 days or 5 halflives prior to Screening Receipt of any protein or antibodybased therapeutic agent within 3 months prior to Screening Prior exposure to telotristat etiprate Use of tobacco, smoking cessation products, or nicotine products within 3 months prior to Screening History of major surgery within 6 months prior to Screening History of any GI surgery that may induce malabsorption History of renal disease, or significantly abnormal glomerular filtration rate (&lt;90 mL/min as calculated using the CockcroftGault equation) at Screening History of hepatic disease, or significantly abnormal liver function tests at Screening History of any clinically significant psychiatric, renal, hepatic, pancreatic, cardiovascular, neurological, endocrinologic, hematological, or GI abnormality History of any active infection within 14 days prior to Screening History of alcohol or substance abuse within 2 years prior to Screening Positive hepatitis panel (including hepatitis B surface antigen and hepatitis C virus antibody) or positive human immunodeficiency virus antibody screens Concurrent conditions that could interfere with safety and/or tolerability measurements Donation or loss of &gt;500 mL of blood or blood product within 3 months prior to Screening Women who are breastfeeding or are planning to become pregnant during the study Positive serum pregnancy test (females only) Positive urine screen for selected drugs of abuse and cotinine Consumption of alcohol within 48 hours prior to study start Consumption of caffeine and/or xanthinecontaining products within 72 hours of study start Consumption of grapefruit, Seville oranges, and grapefruit or Seville orangecontaining products within 72 hours prior to study start Unable or unwilling to communicate or cooperate with the Investigator for any reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>